NCT01433445 is a Phase 1 clinical trial of panobinostat in Idiopathic Myelofibrosis, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT01433445?

NCT01433445 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT01433445?

Interventions in NCT01433445: panobinostat, ruxolitinib.

What condition does NCT01433445 study?

NCT01433445 studies Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia-Vera Myelofibrosis.

Is NCT01433445 still recruiting?

NCT01433445 is currently completed. Last updated 25 June 2021.

Last reviewed 2021-06-25 · How we verify

NCT01433445

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Completed Phase 1 Last updated 25 June 2021

What this trial tests

Phase 1 trial testing panobinostat in Idiopathic Myelofibrosis in 61 participants. Completed in 22 June 2020.

Timeline

1 November 2011

Primary endpoint
22 June 2020

22 June 2020

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	61
Start date	1 November 2011
Primary completion	22 June 2020
Estimated completion	22 June 2020
Sites	10 locations across France, Italy, Ireland, United Kingdom, Germany

Drugs / interventions tested

panobinostat (PANOBINOSTAT) — full drug profile →
ruxolitinib (RUXOLITINIB) — full drug profile →

Conditions studied

Idiopathic Myelofibrosis — all drugs for Idiopathic Myelofibrosis →
Post Essential Thrombocythemia Myelofibrosis — all drugs for Post Essential Thrombocythemia Myelofibrosis →
Post Polycythemia-Vera Myelofibrosis — all drugs for Post Polycythemia-Vera Myelofibrosis →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Idiopathic Myelofibrosis or Post Essential Thrombocythemia Myelofibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess safety as well as establish a Recommended Phase II dose of the combination of panobinostat and ruxolitinib in patients with or without the JAK2V617F mutation who have been diagnosed with primary myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (PET MF), or Post-Polycythemia Vera Myelofibrosis (PPV MF).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.
Meyer SC, Levine RL. · · 2014 · cited 139× · PMID 24583800 · DOI 10.1158/1078-0432.ccr-13-0279
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A, Zhou H, Yang J, Li M, et al · · 2023 · cited 81× · PMID 36797244 · DOI 10.1038/s41392-023-01342-6
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P, Verstovsek S. · · 2017 · cited 78× · PMID 28500170 · DOI 10.1182/blood-2017-04-742288
Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside.
Sarno F, Benincasa G, List M, Barabasi AL, et al · · 2021 · cited 49× · PMID 33785068 · DOI 10.1186/s13148-021-01047-z
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Daver N, Cortes J, Newberry K, Jabbour E, et al · · 2015 · cited 47× · PMID 26088933 · DOI 10.3324/haematol.2015.126821
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, et al · · 2019 · cited 28× · PMID 31920387 · DOI 10.2147/cmar.s212559
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.
Gäbler K, Behrmann I, Haan C. · · 2013 · cited 27× · PMID 24069563 · DOI 10.4161/jkst.25025
Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms.
Brkic S, Meyer SC. · · 2021 · cited 26× · PMID 33403355 · DOI 10.1097/hs9.0000000000000516

Verify or expand the search:

Other trials of panobinostat

Trials testing the same drug.

NCT02386800 — CINC424A2X01B Rollover Protocol · Phase 4 · active not recruiting
NCT01658241 — Panobinostat Biological Correlates Study · Phase 2 · completed
NCT01460940 — A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma · Phase 2 · completed
NCT01261247 — Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · Phase 2 · completed

Other recruiting trials for Idiopathic Myelofibrosis

Currently open trials in the same condition.

NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01433445 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 25 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01433445.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing